Consortium for Discovery and Innovation in Therapy and Medicine



iPPI-DB contains 1650 non-peptidic inhibitors (iPPI) across 13 families of Protein-Protein Interactions. The chemical structures, the physicochemical and the pharmacological profiles of these iPPI are manually extracted from the literature and stored in iPPI-DB.

Meeting announcement

- 2013 -

Drug Discovery Chemistry
San Diego, April 2013

- 2012 -

Molecular Modeling Society
Utrecht, November 2012

Berlin, September 2012

Roscoff, June 2012

Drug Discovery Chemistry
San Diego, April 2012


- 2012 -

Structure-Activity Relationships and Blood Distribution of Antiplasmodial Aminopeptidase-1 Inhibitors.
Déprez-Poulain R, Flipo M, Piveteau C, Leroux F, Dassonneville S, Florent I, Maes L, Cos P, Déprez B.
J Med Chem. 2012 Dec 5. [Epub ahead of print]

A leap into the chemical space of protein-protein interaction inhibitors.
Villoutreix BO, Labbé CM, Lagorce D, Laconde G, Sperandio O.
Curr Pharm Des. 2012;18(30):4648-67.

Setting Up a Bioluminescence Resonance Energy Transfer High throughput Screening Assay to Search for Protein/Protein Interaction Inhibitors in Mammalian Cells.
Couturier C, Déprez B.
Front Endocrinol (Lausanne). 2012;3:100. doi: 10.3389/fendo.2012.00100. Epub 2012 Sep 11.

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
Flipo M, Willand N, Lecat-Guillet N, Hounsou C, Desroses M, Leroux F, Lens Z, Villeret V, Wohlkönig A, Wintjens R, Christophe T, Kyoung Jeon H, Locht C, Brodin P, Baulard AR, Déprez B.
J Med Chem. 2012 Jul 26;55(14):6391-402. doi: 10.1021/jm300377g. Epub 2012 Jul 17.

- 2011 -

The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections.
Lagorce D, Maupetit J, Baell J, Sperandio O, Tufféry P, Miteva MA, Galons H, Villoutreix BO.
Bioinformatics. 2011 Jul 15;27(14):2018-20. doi: 10.1093/bioinformatics/btr333. Epub 2011 Jun 2.

Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening.
Gautier B, Miteva MA, Goncalves V, Huguenot F, Coric P, Bouaziz S, Seijo B, Gaucher JF, Broutin I, Garbay C, Lesnard A, Rault S, Inguimbert N, Villoutreix BO, Vidal M.
Chem Biol. 2011 Dec 23;18(12):1631-9.

Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening.
Villoutreix BO, Laconde G, Lagorce D, Martineau P, Miteva MA, Dariavach P.
PLoS One. 2011;6(6):e21117. doi: 10.1371/journal.pone.0021117.

Invading basement membrane matrix is sufficient for MDA-MB-231 breast cancer cells to develop a stable in vivo metastatic phenotype.
Abdelkarim M, Vintonenko N, Starzec A, Robles A, Aubert J, Martin ML, Mourah S, Podgorniak MP, Rodrigues-Ferreira S, Nahmias C, Couraud PO, Doliger C, Sainte-Catherine O, Peyri N, Chen L, Mariau J, Etienne M, Perret GY, Crepin M, Poyet JL, Khatib AM, Di Benedetto M.
PLoS One. 2011;6(8):e23334. doi: 10.1371/journal.pone.0023334. Epub 2011 Aug 15.

- 2010 -

Targeting AAC-11 in cancer therapy.
Faye A, Poyet JL.
Expert Opin Ther Targets. 2010 Jan;14(1):57-65. doi: 10.1517/14728220903431077. Review.